Don't Miss

Idiopathic Pulmonary Fibrosis (IPF): KOL Insight. offers business critical insights from 12 leading US and European Key Opinion Leaders on what is influencing clinician’s prescribing decisions and which pipeline products are changing the future treatment paradigm for IPF. Learn more.

Sanofi gains Japanese approval for next-generation basal insulin Lantus XR